
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Apogee Therapeutics, Inc. Common Stock (APGE)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: APGE (2-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $96.75
1 Year Target Price $96.75
9 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.38% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.27B USD | Price to earnings Ratio - | 1Y Target Price 96.75 |
Price to earnings Ratio - | 1Y Target Price 96.75 | ||
Volume (30-day avg) 9 | Beta 1.44 | 52 Weeks Range 26.20 - 63.50 | Updated Date 08/15/2025 |
52 Weeks Range 26.20 - 63.50 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.14 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.62 | Actual -1.13 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.21% | Return on Equity (TTM) -34.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1777240111 | Price to Sales(TTM) - |
Enterprise Value 1777240111 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 46109800 | Shares Floating 37619227 |
Shares Outstanding 46109800 | Shares Floating 37619227 | ||
Percent Insiders 7.6 | Percent Institutions 135.79 |
Upturn AI SWOT
Apogee Therapeutics, Inc. Common Stock
Company Overview
History and Background
Apogee Therapeutics is a biotechnology company focused on developing innovative biologics for the treatment of inflammatory and immunologic diseases. It was founded in 2022.
Core Business Areas
- IgE-Mediated Diseases: Developing therapies for diseases driven by IgE antibodies, such as atopic dermatitis and asthma.
- Other Immunologic Diseases: Exploring treatments for other immunologic conditions.
Leadership and Structure
The company has a leadership team comprised of experienced biotechnology executives and scientists. Organizational structure follows standard biotech company lines, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- APG777: APG777 is a lead drug candidate targeting IL-13 for atopic dermatitis. Currently in clinical trials. Market share is not yet applicable due to being in development stage. Competitors include Sanofi/Regeneron (Dupixent), Leo Pharma (Adbry).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on immunology is growing, driven by increasing prevalence of autoimmune and inflammatory diseases, and advancements in biologic therapies.
Positioning
Apogee is positioning itself as a key player in developing novel biologics for immune-mediated diseases, focusing on differentiated approaches to address unmet medical needs.
Total Addressable Market (TAM)
The TAM for inflammatory and immunologic disease therapies is very large. Apogee aims to capture a share of this market through innovative approaches and clinical success. Estimate 150 Billion, Apogee aims for 5-10%.
Upturn SWOT Analysis
Strengths
- Novel drug development platform
- Experienced management team
- Strong focus on immunology
- Targeting unmet medical needs
Weaknesses
- Early stage company
- Reliance on clinical trial success
- Limited financial resources compared to larger competitors
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Positive clinical trial results
- Market approval of lead drug candidate
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- SNY
- LLY
- ABBV
Competitive Landscape
Apogee differentiates itself with its novel drug development platform targeting specific immunological pathways, but faces significant competition from established pharmaceutical giants with greater resources and established products.
Growth Trajectory and Initiatives
Historical Growth: Since its founding, growth is based on the progress in clinical trials and development of key therapies
Future Projections: Analyst estimates project future growth based on the successful development and commercialization of lead drug candidate, APG777.
Recent Initiatives: Advancing APG777 through clinical trials, expanding its pipeline, and securing strategic partnerships.
Summary
Apogee Therapeutics is an early-stage biotechnology company focused on novel biologics for immunology. Their lead drug candidate, APG777, shows promise, but the company faces risks associated with clinical trials and competition. Securing partnerships and successful clinical outcomes are essential for future growth. Financial resources and cashflows need to be monitored as the company grows.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and comprehensive research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apogee Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2023-07-14 | CEO & Director Dr. Michael Thomas Henderson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 196 | |
Full time employees 196 |
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.